Cefepime is a fourth-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs).

• Pneumonia

• Febrile neutropenia (empiric therapy)

• Uncomplicated and complicated urinary tract infections

• Uncomplicated skin and skin structure infections

• Complicated intra-abdominal infections (with metronidazole)

Adults (CrCl >60 mL/min):

• Pneumonia: 1–2 g IV every 8–12 hours for 10 days
• Febrile neutropenia: 2 g IV every 8 hours for 7 days
• UTIs: 0.5–2 g IV every 12 hours for 7–10 days
• Skin infections: 2 g IV every 12 hours for 10 days
• Intra-abdominal (with metronidazole): 2 g IV every 8–12 hours for 7–10 days

Pediatrics (2 months–16 years):

• 50 mg/kg every 12 hours (every 8 hours for febrile neutropenia)

• Common: rash, diarrhea, nausea, vomiting, pruritus, fever, headache

• Serious: encephalopathy, seizures, hallucinations, myoclonus, neurotoxicity (especially in renal impairment)

• Known hypersensitivity to cefepime, cephalosporins, penicillins, or other beta-lactams

• Hypersensitivity to corn products (due to dextrose content)

• Hypersensitivity reactions, including cross-reactivity with penicillins
• Risk of neurotoxicity, especially in renal impairment
• C. difficile-associated diarrhea
• Potential for drug-resistant bacteria development
• Caution in patients with diabetes, GI disease, or when co-administered with nephrotoxic agents